-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Nurix Therapeutics, Raises Price Target to $33

Benzinga·07/10/2026 13:35:48
Listen to the news
RBC Capital analyst Brian Abrahams maintains Nurix Therapeutics (NASDAQ:NRIX) with a Outperform and raises the price target from $30 to $33.